Everest VC

Everest VC’s portfolio, listed on its website as of May 2026, spans biopharma, integrated circuits, new energy storage, robotics, low-altitude economy, aerospace, green hydrogen, 6G telecommunications, quantum technology, enterprise software, and embodied intelligence. The largest disclosed concentrations are in biopharma (27 companies) and semiconductors (23 companies). The firm does not publicly detail check sizes, but the stage range runs from seed to pre-IPO.

No named investment principals are publicly disclosed. The firm’s website does not publish a team page, and no leadership bios, LinkedIn profiles, or regulatory filings identifying key decision-makers could be located (Altss research). For an allocator, this means independent reference-checking on the investment committee and sourcing partners is required before diligence.

Everest VC is structured as a venture capital and private equity asset manager, not a single family office. It operates through corporate entities 朗玛峰创业投资有限公司 (Shenzhen) and 北京朗玛峰创业投资管理有限公司 (Beijing). The firm does not disclose a founding family, wealth origin, or external LP base, but its corporate registration and portfolio scale are consistent with a manager rather than a proprietary family vehicle.

All publicly visible activity points toward a direct-investment model. Everest VC’s website lists 85 portfolio companies by name across 11 sector verticals, with no mention of LP commitments to third-party funds, fund-of-funds structures, or co-investment club participation. The absence of English-language fund disclosures limits visibility into whether any sleeves operate through feeder funds.

Everest VC does not publicly describe its co-investment practices. The website does not reference syndicate partners, co-investment vehicles, or GP relationships. Given the firm’s China-centric, hard-tech mandate, co-investment partners — if any — are likely to be domestic strategic investors or state-guided industrial funds rather than Western GPs.

Everest VC does not publish a formal exclusion list. Its portfolio concentration in capital-intensive, policy-aligned hard-tech — biopharma, semiconductors, aerospace, and energy transition — implies a de facto avoidance of consumer internet, enterprise SaaS outside the 6G/enterprise service vertical, and business models dependent on non-Chinese supply chains. No consumer-brand or platform-economy companies appear in its disclosed holdings.

Sourcing methodology is not publicly described. The firm’s dual-headquarters structure in Beijing’s Zhongguancun district and Shenzhen’s Qianhai fund town positions it within China’s two densest startup ecosystems. Beijing provides proximity to university and state-lab spinouts in biotech and semiconductors; Shenzhen anchors access to hardware and manufacturing innovation. Without a published team roster, the sourcing engine likely depends on deep regional networks rather than a public brand.